29.59

4.37% 1.24

After Hours: 29.59

Agios Pharmaceuticals Inc (AGIO)

Overview News Price History Option Chain Financials Discussions Forecast

Agios Pharmaceuticals Inc stock is traded at $29.59, with a volume of 726.22K. It is up +4.37% in the last 24 hours and down -1.23% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Previous Close:

$28.35

Open:

$28.78

24h Volume:

726.22K

Relative Volume:

0.71

Market Cap:

$1.73B

Revenue:

$54.03M

Net Income/Loss:

$-412.78M

P/E Ratio:

-4.1565

EPS:

-7.1189

Net Cash Flow:

$-377.29M

1W Performance:

+5.19%

1M Performance:

-1.23%

6M Performance:

-19.18%

1Y Performance:

-3.80%

1-Day Range:

$28.59

$30.16

1-Week Range:

$27.40

$30.16

52-Week Range:

$22.24

$46.00

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name

Agios Pharmaceuticals Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

617-649-8600

Address

88 SIDNEY STREET, CAMBRIDGE, MA

Employee

540

Twitter

@AgiosPharma

Next Earnings Date

2024-10-31

Latest SEC Filings

AGIO's Discussions on Twitter

Compare AGIO vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AGIO Agios Pharmaceuticals Inc	29.59	1.66B	54.03M	-412.78M	-377.29M	-7.1189
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-24-25	Initiated	Truist	Buy
Nov-20-25	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-24-25	Initiated	H.C. Wainwright	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight
Nov-17-22	Upgrade	Goldman	Sell → Neutral
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Dec-03-21	Initiated	BofA Securities	Buy
Jul-30-21	Downgrade	Goldman	Neutral → Sell
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
May-23-19	Resumed	Goldman	Neutral
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy
Apr-11-18	Reiterated	Credit Suisse	Outperform
Feb-15-18	Reiterated	Needham	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-10-17	Reiterated	Needham	Buy
Aug-08-17	Reiterated	SunTrust	Buy
Aug-02-17	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-17	Downgrade	Janney	Buy → Neutral
Jan-17-17	Upgrade	Oppenheimer	Perform → Outperform
Oct-24-16	Initiated	Needham	Buy
Jun-13-16	Upgrade	JP Morgan	Neutral → Overweight
May-18-16	Reiterated	SunTrust	Buy

View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

Mar 25, 2026

AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - marketscreener.com

Mar 25, 2026

Mar 24, 2026

Agios Pharmaceuticals stock declines 23% in 6 months: Here's why - MSN

Mar 24, 2026

The Gross Law Firm Announces an Investigation on Behalf of Agios Pharmaceuticals, Inc. (AGIO) Shareholders Who May Have Been Affected by Fraud - PR Newswire

Mar 24, 2026

Mar 22, 2026

Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to "Hold" at Wall Street Zen - MarketBeat

Mar 22, 2026

Mar 21, 2026

AGIO PE Ratio & Valuation, Is AGIO Overvalued - Intellectia AI

Mar 21, 2026

AGIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 21, 2026

Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis - Barchart.com

Mar 18, 2026

Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - Yahoo Finance

Mar 18, 2026

ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - marketscreener.com

Mar 18, 2026

Mar 17, 2026

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gro - GuruFocus

Mar 17, 2026

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation - PR Newswire

Mar 17, 2026

Liquidity Mapping Around (AGIO) Price Events - Stock Traders Daily

Mar 17, 2026

Mar 16, 2026

HighVista Strategies LLC Buys 125,171 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat

Mar 16, 2026

Does UAE Thalassemia Approval for PYRUKYND Reframe the Bull Case for Agios Pharmaceuticals (AGIO)? - simplywall.st

Mar 16, 2026

Mar 14, 2026

Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at Wall Street Zen - MarketBeat

Mar 14, 2026

Mar 13, 2026

Cantor Fitzgerald Keeps Overweight on Agios Pharmaceuticals, Inc. (AGIO) Mar 2026 - Meyka

Mar 13, 2026

Mar 12, 2026

AGIO SEC FilingsAgios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 12, 2026

Agios Pharmaceuticals (AGIO) price target decreased by 34.97% to 32.77 - MSN

Mar 12, 2026

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com

Mar 12, 2026

Mar 11, 2026

A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND Approval And GCC Expansion - simplywall.st

Mar 11, 2026

Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - Morningstar

Mar 11, 2026

Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law ViolationsContact The Gross Law Firm for Details- AGIO - lelezard.com

Mar 11, 2026

Mar 10, 2026

Agios Pharmaceuticals, Inc. Investigated Regarding Potential Sec - GuruFocus

Mar 10, 2026

Mar 09, 2026

Agios Pharmaceuticals (AGIO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan

Mar 09, 2026

Agios (NASDAQ: AGIO) executive sells 2,959 shares to cover RSU tax - Stock Titan

Mar 09, 2026

Agios Pharmaceuticals: Worthy Of Accumulation (NASDAQ:AGIO) - Seeking Alpha

Mar 09, 2026

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides - AOL.com

Mar 09, 2026

Zacks Research Analysts Lift Earnings Estimates for AGIO - MarketBeat

Mar 09, 2026

Mar 08, 2026

Stock Analysis: Is Agios Pharmaceuticals Inc. stock showing strong momentum2026 Fundamental Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn

Mar 08, 2026

Mar 07, 2026

AGIO Earnings History & Surprises | EPS & Revenue Results | AGIOS PHARMACEUTICALS INC (NASDAQ:AGIO) - ChartMill

Mar 07, 2026

Why Agios Pharmaceuticals Inc. stock could benefit from AI revolutionShort Setup & Risk Managed Investment Entry Signals - Naître et grandir

Mar 07, 2026

Mar 06, 2026

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com

Mar 06, 2026

FY2028 Earnings Forecast for AGIO Issued By Zacks Research - MarketBeat

Mar 06, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Mar 06, 2026

Mar 05, 2026

Why (AGIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Mar 05, 2026

Insider Sell Alert: Washburn Theodore James Jr. Sells Shares of Agios Pharmaceuticals Inc (AGIO) - GuruFocus

Mar 05, 2026

AGIO: Citigroup Raises Price Target Amidst Continuous Buy Ratings | AGIO Stock News - GuruFocus

Mar 05, 2026

Citigroup Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat

Mar 05, 2026

Agios Pharmaceuticals (AGIO) Target Price Raised by Citi - GuruFocus

Mar 05, 2026

Mar 04, 2026

Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors o - GuruFocus

Mar 04, 2026

How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets - Yahoo Finance

Mar 04, 2026

Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO – Company AnnouncementFT.com - Financial Times

Mar 04, 2026